Synergy CHC (SNYR) Competitors $3.79 -0.18 (-4.53%) As of 07/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SNYR vs. GNLX, ATOS, KRRO, ACTU, IOBT, TARA, BHST, CLLS, SKYE, and INKTShould you be buying Synergy CHC stock or one of its competitors? The main competitors of Synergy CHC include Genelux (GNLX), Atossa Genetics (ATOS), Korro Bio (KRRO), Actuate Therapeutics (ACTU), IO Biotech (IOBT), Protara Therapeutics (TARA), BioHarvest Sciences (BHST), Cellectis (CLLS), Skye Bioscience (SKYE), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. Synergy CHC vs. Its Competitors Genelux Atossa Genetics Korro Bio Actuate Therapeutics IO Biotech Protara Therapeutics BioHarvest Sciences Cellectis Skye Bioscience MiNK Therapeutics Synergy CHC (NASDAQ:SNYR) and Genelux (NASDAQ:GNLX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Do analysts prefer SNYR or GNLX? Synergy CHC currently has a consensus target price of $10.00, suggesting a potential upside of 163.85%. Genelux has a consensus target price of $17.75, suggesting a potential upside of 431.44%. Given Genelux's higher probable upside, analysts plainly believe Genelux is more favorable than Synergy CHC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media favor SNYR or GNLX? In the previous week, Genelux had 1 more articles in the media than Synergy CHC. MarketBeat recorded 2 mentions for Genelux and 1 mentions for Synergy CHC. Synergy CHC's average media sentiment score of 1.89 beat Genelux's score of 0.94 indicating that Synergy CHC is being referred to more favorably in the media. Company Overall Sentiment Synergy CHC Very Positive Genelux Positive Which has higher earnings and valuation, SNYR or GNLX? Synergy CHC has higher revenue and earnings than Genelux. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC$34.83M1.00$2.12MN/AN/AGenelux$10K12,611.84-$29.87M-$0.88-3.80 Do institutionals and insiders believe in SNYR or GNLX? 37.3% of Genelux shares are held by institutional investors. 56.6% of Synergy CHC shares are held by insiders. Comparatively, 9.3% of Genelux shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is SNYR or GNLX more profitable? Synergy CHC's return on equity of -8.48% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHCN/A -8.48% 12.75% Genelux N/A -93.04%-74.17% SummarySynergy CHC beats Genelux on 7 of the 12 factors compared between the two stocks. Get Synergy CHC News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNYR vs. The Competition Export to ExcelMetricSynergy CHCCONS PD IndustryStaples SectorNASDAQ ExchangeMarket Cap$36.50M$33.37B$16.19B$9.50BDividend YieldN/A2.53%3.14%4.01%P/E RatioN/A32.5520.1020.05Price / Sales1.001.8545.6789.38Price / Cash14.9316.8715.0258.56Price / Book-1.988.596.135.87Net Income$2.12M$1.19B$691.82M$258.55M7 Day Performance4.99%3.90%28.39%3.73%1 Month Performance51.60%7.62%3.96%11.75%1 Year PerformanceN/A-2.55%1.95%18.03% Synergy CHC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYRSynergy CHC4.0745 of 5 stars$3.79-4.5%$10.00+163.9%N/A$36.50M$34.83M0.0040Positive NewsGap DownGNLXGenelux1.2346 of 5 stars$3.25-3.8%$17.75+446.2%+74.0%$122.64MN/A-3.6910Analyst ForecastGap UpATOSAtossa Genetics3.0319 of 5 stars$0.94-0.1%$6.17+558.8%-40.4%$120.77MN/A-4.458News CoveragePositive NewsKRROKorro Bio1.7879 of 5 stars$12.85-1.0%$102.43+697.4%-69.4%$120.57M$2.27M-1.3670News CoverageAnalyst ForecastACTUActuate Therapeutics2.252 of 5 stars$6.15-0.9%$20.50+233.6%N/A$120.57MN/A0.0010News CoverageIOBTIO Biotech3.7887 of 5 stars$1.79+5.1%$9.33+422.6%+53.7%$118.26MN/A-1.2030News CoveragePositive NewsGap UpTARAProtara Therapeutics2.1594 of 5 stars$3.07-3.0%$20.50+568.8%+45.4%$118.25MN/A-1.7830BHSTBioHarvest SciencesN/A$7.05flat$13.67+93.9%N/A$115.80M$27.70M-14.10N/ANews CoverageCLLSCellectis3.1138 of 5 stars$2.06-4.2%$4.00+94.2%+22.9%$114.50M$49.22M-2.40290Positive NewsGap UpSKYESkye Bioscience2.5361 of 5 stars$3.70-6.0%$16.60+349.3%-33.7%$114.45MN/A-4.5111News CoverageGap UpINKTMiNK Therapeutics2.8426 of 5 stars$28.66-29.4%$37.50+30.9%+99.6%$114MN/A-11.3530Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Genelux Competitors Atossa Genetics Competitors Korro Bio Competitors Actuate Therapeutics Competitors IO Biotech Competitors Protara Therapeutics Competitors BioHarvest Sciences Competitors Cellectis Competitors Skye Bioscience Competitors MiNK Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNYR) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy CHC Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synergy CHC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.